The Boston Patent Law Association is hosting a panel discussion on the Supreme Court’s recent case FTC v. Actavis, Inc. (June 17, 2013) concerning the antitrust implications of reverse payment settlements (so-called “pay-for-delay” settlements) in the context of branded vs. generic ANDA litigation in the pharmaceutical industry.
WilmerHale Partner Mark Ford will be a featured speaker at this event.
Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.
Thank you for your interest in WilmerHale.
